aprepitant Emend oral
Selected indexed studies
- Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (Lancet Oncol, 2020) [PMID:31838011]
- AGA Clinical Practice Guideline on Management of Gastroparesis. (Gastroenterology, 2025) [PMID:40976635]
- A simple extemporaneous oral suspension of aprepitant yields sufficient pharmacokinetic exposure in children. (J Oncol Pharm Pract, 2023) [PMID:35377726]
_Worker-drafted node — pending editorial review._
Connections
aprepitant Emend oral is a side effect of
Sources
- Aprepitant: a review of its use in the prevention of nausea and vomiting. (2009) pubmed
- AGA Clinical Practice Guideline on Management of Gastroparesis. (2025) pubmed
- Pharmacokinetic evaluation of fosaprepitant dimeglumine. (2010) pubmed
- Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (2020) pubmed
- A simple extemporaneous oral suspension of aprepitant yields sufficient pharmacokinetic exposure in children. (2023) pubmed
- Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial. (2025) pubmed
- Relative bioavailability of an extemporaneously prepared aprepitant oral suspension in healthy adults. (2019) pubmed
- Stability of an extemporaneous oral liquid aprepitant formulation. (2009) pubmed
- Systemic Medication for the Treatment of Prurigo Nodularis-A Systematic Review. (2023) pubmed
- Comparison of oral aprepitant and intravenous fosaprepitant for prevention of chemotherapy-induced nausea and vomiting in pediatric oncology patients: a randomized phase III trial. (2024) pubmed